arrow_back Back Filing freshness 10-Q Q2 FY2027 SEC EDGAR

Replimune Group, Inc.

REPL
$20.02 ▼ -0.65 (-3.14%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
39 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Replimune Group, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -14.6% ↗
FCF / Share $-0.45 ↗
Trailing P/E —
Price / Book 9.3x
FCF Yield —
Debt / Equity 0.49
info Valuation on last close. End-of-day price, Nov 5, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-69.77M
↑ +19.5% —
FCF / Share Free cash flow per share
$-0.45
↑ +42.0% —
Long-Term Debt Long-term obligations
$99.77M
↑ +18.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
3
Financial Health ↑
30
Cash Quality ↑
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 39 quarters